UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. Nail psoriasis
- 2. 外陰部硬化性苔癬 vulvar lichen sclerosus
- 3. 口腔扁平苔癬：マネージメントおよび予後 oral lichen planus management and prognosis
- 4. 水疱性類天疱瘡のマネージメントおよび予後 management and prognosis of bullous pemphigoid
- 5. 乾癬の治療 treatment of psoriasis
English Journal
- Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy.
- Hofmann M, Salgo R, Aschoff R, Luger TA, Meurer M, Bräutigam M, Thaci D.SourceDepartment of Dermatology, Venereology and Allergology, Goethe-University, Theodor-Stern Kai 7, 60590, Frankfurt/Main, Germany.
- Archives of dermatological research.Arch Dermatol Res.2013 Apr;305(3):215-21. doi: 10.1007/s00403-012-1297-2. Epub 2012 Dec 16.
- Currently, there are no accurate and simple methods available to measure this risk of atrophy in patients treated with topical glucocorticosteroids. In the present clinical trial, we validated a new score (Dermaphot(®) score) to assess the atrophogenic potential of glucocorticosteroids. 36 healthy
- PMID 23242470
- Efficacy of topical calcineurin inhibitors in vitiligo.
- Wong R, Lin AN.SourceFaculty of Medicine and Dentistry, Canada.
- International journal of dermatology.Int J Dermatol.2013 Apr;52(4):491-6. doi: 10.1111/j.1365-4632.2012.05697.x. Epub 2013 Jan 20.
- Topical tacrolimus and pimecrolimus are indicated for the treatment of atopic dermatitis, but they have been studied in many off-label uses. We reviewed the English language literature to define their roles in treatment of vitiligo. Double-blind studies show that tacrolimus 0.1% ointment combined wi
- PMID 23331250
- Inhibition of putative hyalurosome platform in keratinocytes as a mechanism for corticosteroid-induced epidermal atrophy.
- Barnes L, Ino F, Jaunin F, Saurat JH, Kaya G.SourceDepartment of Dermatology, University Hospital of Geneva, Geneva, Switzerland.
- The Journal of investigative dermatology.J Invest Dermatol.2013 Apr;133(4):1017-26. doi: 10.1038/jid.2012.439. Epub 2012 Dec 6.
- The main limitation of using topical corticosteroids in dermatology is their atrophic effects on the skin. We have previously proposed a molecular platform composed of CD44, EGFR, and hyaluronate synthase (HAS) that is functionally defective in dermatoporosis, a chronic cutaneous insufficiency/fragi
- PMID 23223147
Related Links
- 商品No 商 品 名 濃度 / 数 量 価 格 PT-031, ティモベート クリーム Temovate 5% 45g Cream made in USA 45g 1本 18,200円 ... ティモベイトは体内のホルモンに働きかけ、肌の不快な症状を抑える治療薬です。 赤み、痒み、かさつき、炎症 ...
- Temovate official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. ... Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is ...
Related Pictures
